SCHEMBL26200516

SCHEMBL26200516

C=C1OCC(c2ccco2)=C1c1cccs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.44
HPGD P15428 4/20 0.44
KDM4E B2RXH2 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HSD17B10 Q99714 2/20 0.44
TOP1 P11387 1/20 0.43
POLB P06746 5/20 0.39
DCTPP1 Q9H773 2/20 0.37
HIF1A Q16665 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
ADORA2A P29274 4/20 0.36
ADORA1 P30542 3/20 0.36
ADORA2B P29275 2/20 0.36
F2 P00734 1/20 0.35
MAPT P10636 5/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
RECQL P46063 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22246016 0.84 ALDH1A1 (0.46) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL26200495 0.73 LTA4H (0.33) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL26200515 0.73 LTA4H (0.33) MAPT
SCHEMBL521943 0.72 ALDH1A1 (0.62) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL29696576 0.66 ALDH1A1 (0.54) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL22246046 0.65 KMT2A (0.44) ALDH1A1HPGDKDM4ESMN1; SMN2POLB
SCHEMBL3087312 0.65 ALDH1A1 (0.54) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL18671634 0.63 ALDH1A1 (0.51) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL28741694 0.63 ALDH1A1 (0.51) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL3087314 0.63 ALDH1A1 (0.51) ALDH1A1HPGDKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744826-B2 Compounds and methods of treating retinal degeneration CASE WESTERN RESERVE UNIVERSITY (US) 2023-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744826-B2 Compounds and methods of treating retinal degeneration ALDH1A2, PDE6D, PDE6C ALDH1A1 212/4885HPGD 238/4885KDM4E 4656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.